He unexpectedly becomes a father at the start of his life, and the mother of his child is a national

A tremendous fear gripped Li Qingshan—

It wasn't the fear of losing money—he hadn't invested much—but the fear that he had almost ignored Chen Hao's clear warning because of greed!

"I'll level! I'll level right away!"

Li Qingshan practically shouted it out, his fingers trembling, but he opened the trading interface at lightning speed.

Find my NTEC long position, grit my teeth, and click the "Close All Positions" button!

A notification pops up indicating that the operation is complete.

Average transaction price: US$36.48.

It was almost $0.4 lower than the price he had before he hesitated.

A small portion of the profits were given back.

But Li Qingshan couldn't care less about the little money he earned at that moment.

His eyes were fixed intently on the trading screen.

Less than a minute after he finished closing his position, a massive sell order suddenly appeared, like a heavy hammer slamming down!

NTEC's stock price plummeted like a kite with a broken string!

$36.00!

$35.50!

$35.00!

$34.50!

It plummeted almost vertically!

Trading volume surged dramatically!

A shockingly long bearish candlestick appeared on the candlestick chart!

Li Qingshan stared dumbfounded at the wildly fluctuating numbers and the steeply descending green line on the screen, his back instantly drenched in cold sweat.

His heart pounded wildly, and a chill of fear shot from the soles of his feet to the top of his head.

My God... it really fell!

It fell so hard!

So fast!

If he hadn't listened to Chen Hao, even if he had closed his position a minute later, no, even thirty seconds later, most of his profits would have been wiped out instantly!

If you're greedy and wait a little longer for a rebound, you'll likely end up trapped at the top of the market!

Chen Hao's prediction... was simply amazing!

It is currently in the final stage before FDA (U.S. Food and Drug Administration) approval.

Over the past two months, this stock has risen from $40 to around $78, almost doubling in value.

The surge was primarily driven by extremely high market expectations for the approval of "BH-101" and several optimistic industry analyst reports.

The company's CEO has also expressed his confidence in obtaining approval on several public occasions recently.

However, after in-depth research, Chen Hao discovered several dangerous signals that had been ignored or deliberately downplayed by the market.

First, he found a "letter from a reader" published in an authoritative medical journal, but which had not attracted widespread attention from mainstream financial media.

This letter came from several independent neurology experts who raised methodological questions about certain subgroup data presented in the Phase III clinical trial of "BH-101".

They argued that the "significance" of its efficacy might have been exaggerated by statistical methods, and pointed out the lack of long-term safety data.

Such questions from the academic community are often a key focus of the FDA's review process.

Secondly, he noticed the company's main competitor, another larger pharmaceutical company, Genetron.

Two weeks ago, the company suddenly announced an acceleration of the development of its competing drug and released impressive early animal test data.

This means that even if "BH-101" is approved, it will soon face fierce market competition and pricing pressure, and the profit potential brought by the market exclusivity period will be compressed.